The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria and West Nile fever.

More than $107 million was raised to support the St. Jude mission of finding cures and saving children battling cancer and other life-threatening diseases during the organization's recent 13th annual Thanks and Giving campaign.

A  recent research study showed that stroke patients receiving clot-busting medications before arriving at the hospital have a lower risk for disability.

Real Endpoints recently conducted research that found significant variability in treatment preferences among multiple sclerosis patients, as well as a difference in how patients define value in MS therapies compared to payers and physicians.

A National Institutes of Health-supported report found that in older men with low testosterone, one year of testosterone treatment improved bone density and corrected anemia of both known and unknown causes, but also increased the volume of coronary artery plaque.

A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.

Patients hospitalized or treated in the emergency room for depression, anxiety, post-traumatic stress disorder or other psychiatric disorders may have an increased risk for stroke, particularly in the 15 days following their psychiatric diagnosis.

Although tissue plasminogen activator (tPA)  treatment for strokes is increasing over time, minorities, women and residents of 11 Southeastern states that make up the “Stroke Belt” are left behind when it comes to receiving tPA.

A new study suggests that the same estrogen therapy used to treat osteoporosis can lead to healthier teeth and gums.

Cancer patients with a nurse navigator rated their care higher and reported fewer problems than patients without one, according to a study recently published in the Journal of Clinical Oncology.  

Shire recently launched "Rare Count" in honor of Rare Disease Day and the 350 million people worldwide living with rare diseases, which equates to nearly one in 20 global citizens.

Vifor Pharma will pay $20 million to ChemoCentryx for the rights to sell a renal disease drug in all markets outside the United States and China, the company announced recently.

A combination drug therapy for the treatment of lung cancer has begun phase II testing with approximately 60 patients experiencing progression or relapse of the disease, Boehringer Ingelheim announced recently.

Physicians who feel burned out are far less likely to believe their work has meaning or that it is any longer an important part of their life, a recent study has found, according to the American Medical Association.

Positive early results from a drug tested on people with advanced bladder cancer continued in a larger data set reviewed recently, the drug's maker, AstraZeneca, has reported.

Scientists from the National Institutes of Health (NIIH) have discovered that an antibody related to the early onset of HIV binds to the immunodeficiency virus and other cells rather than being destroyed as was expected, the NIH reported recently.

Merck has launched a digital component to its campaign to improve outcomes for people suffering from infectious diseases, the company announced recently.

A genetically engineered compound that blocks the production of a protein known as tau could lead the way toward preventing a variety of disorders, including Alzheimer's disease, the National Institutes of Health (NIH) reported recently.

Merck has ceased a study of the drug verubecestat for the treatment of people with mild to moderate Alzheimer’s disease after an external monitoring panel found “virtually no chance of finding a positive clinical effect," the company announced recently.

An investigational malaria vaccine protected "a significant proportion" of adults in Mali, Africa, where it is being tested by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the NIH reported recently.